[TOAC1, Arg2] TG

General Information


DRACP ID  DRACP02456

Peptide Name   [TOAC1, Arg2] TG

Sequence  XRLXGGLXGIX

Sequence Length  11

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic (Derived from TG)

Type  Synthetic peptide

Classification

  

Active ACP Membrane lysis



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
T67 Astrocytoma Carcinoma EC50=8 μM MTT assay 24 h 1
HeLa Human papillomavirus-related endocervical adenocarcinoma Carcinoma EC50=9 μM MTT assay 24 h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Human dermal fibroblasts: EC50=15 μM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Oct (Fatty acid 1-Octanoyl)

C-terminal Modification  Free

Other Modification  X(1)=TOAC; X(4/8)=Aib; X(11)=Lol (Amino alcohol leucinol)

Chiral  L



Physicochemical Information


Formula  C30H48N10O4

Absent amino acids  ACDEFHKMNPQSTVWY

Common amino acids  X

Mass  123133

Pl  10.55

Basic residues  1

Acidic residues  0

Hydrophobic residues  3

Net charge  1

Boman Index  266

Hydrophobicity  58.18

Aliphatic Index  106.36

Half Life 
  /

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  3

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 27039838

Title  The rational search for selective anticancer derivatives of the peptide Trichogin GA IV: a multi-technique biophysical approach

Doi 10.1038/srep24000

Year  2016

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPS_9390

DRACP is developed by Dr.Zheng's team.